Guidance and quality standards Awaiting development
Showing 341 to 345 of 345
Title | Type |
---|---|
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477 | Technology appraisal guidance |
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments TS ID 11952 | Technology appraisal guidance |
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments TSID 11915 | Technology appraisal guidance |
Zavegepant for treating acute migraine TSID 11998 | Technology appraisal guidance |
Zuranolone for treating severe postnatal depression ID6431 | Technology appraisal guidance |